Mary&May Six Peptide review: the complex does not disclose a split

The serum name describes a grouped product

The heading identifies Mary&May 6 Peptide Complex Serum. Its accompanying explanation refers to six types or kinds of peptides and presents them as a combined formulation story. These are the manufacturer’s identity and count statements, rather than six separate preparations examined by this publication.

Keeping the named serum as the subject avoids turning its headline into a specification for copper peptides generally. A count may help organize the ingredient description, but it does not reveal how much of the bottle consists of the grouping or how each constituent is allocated. The physical product and its package version were not inspected.

The captured declaration identifies six names

The complete retained list contains Copper Tripeptide-1, Hexapeptide-11, Hexapeptide-9, Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1 and Tripeptide-1. These are literal entries in the manufacturer declaration. Their names support the six-peptide description without supplying six individual quantitative specifications.

The record also includes non-peptide formulation ingredients. A complete list of names is therefore not the same as a complete numerical recipe. The grade-and-purity article discusses why naming a substance does not establish its purity, active fraction or assayed amount in a finished preparation.

A combined complex leaves constituent shares open

The highlighted six-peptide-complex wording describes ingredients presented together. The source explanation does not disclose a total complex percentage or each peptide’s share in the examined passages. There is no basis here for assuming one-sixth of the blend belongs to Copper Tripeptide-1.

That unresolved split should not be replaced by a convenient arithmetic example. Supplier dilution, active-content basis and analytical methods would be separate documentation questions. For another record about a counted mixture, see the COSRX review. A common count is useful for comparison of wording, without establishing equal formulations or equivalent clinical strength.

The count still has a legitimate descriptive role: it directs attention to the named mixture rather than an unspecified single active. The limit arises when that qualitative grouping is treated as a disclosed material amount. Even a total complex percentage, if separately supplied, would need a definition before it could establish the amount of one constituent. This particular record supplies neither that total nor an individual split, so both questions remain open without a calculated substitute.

Ordering rules prevent a false recipe

The captured ingredient sequence can make an unquantified complex look more specific than it is. Reconstructing its amounts from that sequence would go beyond the disclosed information. A lower position cannot be converted into a particular percentage for this review.

FDA’s US cosmetic labeling guide describes descending order with exceptions, including flexible order for ingredients at no more than one percent after higher-concentration ingredients. That is a separate US framework, not a compliance determination for this manufacturer record. It explains an inference limit without establishing where any of the six entries actually falls within a concentration band.

Synergy is the company’s explanation

Mary&May describes the selected peptides as working synergistically and uses wrinkle-related appearance language. Those statements are attributed manufacturer rationale, rather than a controlled comparison reproduced by this publication. The examined short text does not identify an experiment separating the combined mixture from each constituent alone.

A synergy description therefore cannot substitute for the missing quantities or show that copper accounts for a particular result. The firmness-and-results guide separates intended effects from evidence about a named finished preparation. This review neither confirms the claimed relationship experimentally nor treats missing methods as proof that no relationship is possible.

The study gap remains a gap in this reading

No complete finished-serum study report, control comparison or quantified result panel was established by the selected product passages. That is a statement about the material examined here, not a claim that the company has never collected any evidence. The distinction matters when a brief merchant page is the available record.

The six declared names remain useful identification information despite that limit. They simply cannot supply an unreported participant group, assessment method or numerical outcome. A reader who wants to investigate the quantitative claim needs documentation tied to this product, rather than a study or concentration from another brand with similar peptide terminology.

A precise conclusion does not need a concentration guess

Mary&May names a serum, describes a six-peptide grouping and supplies a complete captured list containing a copper-named peptide. The individual amounts, complex loading and analytical basis remain unresolved in the official record. That conclusion preserves the information available without adding a stronger formulation claim.

The Naturium review examines a different declaration question, and the original product comparison places several kinds of record side by side. Neither provides a missing recipe for this serum. The number six is informative as a count; it becomes misleading only when rewritten as a constituent quantity or a predicted benefit.